Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial

YAO GAO,a JIA GUO,a XULI BAO,a FANG XIONG,a YANPIN MA,a BINGQIN TAN,a LELE YU,a YONG ZHAO,b JUN LU

aHepatology and Cancer Biotherapy Ward, Beijing YouAn Hospital, Capital Medical University, Beijing, People’s Republic of China; bThe State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, People’s Republic of China

Key Words. Hepatocellular carcinoma • Natural killer T cells • Immunotherapy

TRIAL INFORMATION

- ClinicalTrials.gov Identifier: NCT03175679
- Sponsors: Beijing YouAn Hospital
- Principal Investigator: Jun Lu
- IRB Approved: Yes

LESSONS LEARNED

- Administration of autologous invariant natural killer T (iNKT) cells was safe and well-tolerated in patients with hepatocellular carcinoma (Barcelona Clinic Liver Cancer stage B/C).
- Expanded iNKT cells produced T-helper 1-like responses with possible antitumor activity.
- No severe adverse events were observed in any of the enrolled patients, including one patient who received $10^{10}$ in vitro-expanded autologous iNKT cells as a single infusion.

ABSTRACT

Background. Invariant natural killer T cells co-express T-cell antigen receptor and natural killer (NK) cell receptors. Invariant natural killer T (iNKT) cells exhibit antitumor activity, but their numbers and functions are impaired in patients with hepatocellular carcinoma (HCC). The adoptive transfer of iNKT cells might treat advanced HCC.

Methods. This phase I study (NCT03175679) enrolled 10 patients with HCC (Barcelona Clinic Liver Cancer [BCLC] stage B/C) at Beijing YouAn Hospital (April 2017 to May 2018). iNKT cells isolated from peripheral blood mononuclear cells (PBMCs) were expanded and alpha-galactosylceramide (α-GalCer)-pulsed. Dosage escalated from $3 \times 10^7$ to $6 \times 10^7$ to $9 \times 10^7$ cells/m² (3+3 design). An exploratory dose trial (1 $\times 10^{10}$ cells/m²) was conducted in one patient.

Results. Expanded iNKT cells produced greater quantities of T-helper 1 (Th1) cytokines (e.g., interferon-gamma, perforin, and granzyme B) but less interleukin-4 than nonexpanded iNKT cells. Circulating numbers of iNKT cells and activated NK cells were increased after iNKT cell infusion. Most treatment-related adverse events were grade 1–2, and three grade 3 adverse events were reported; all resolved without treatment. Four patients were progression-free at 5.5, 6, 7, and 11 months after therapy, and one patient was alive and without tumor recurrence at the last follow-up. Five patients died at 1.5 to 11 months after treatment.

Conclusion. Autologous iNKT cell treatment is safe and well-tolerated. Expanded iNKT cells produce Th1-like responses with possible antitumor activity. The antitumor effects of iNKT cell infusion in patients with advanced HCC merit further investigation.

DISCUSSION

iNKT cells have potent antitumor activities [1–4]. Decreases in iNKT cell number and function correlate with a poor clinical outcome [5, 6]. Therefore, activated iNKT cells could be used therapeutically, either alone or in combination with other treatments, to reverse the defects in iNKT cell number and function [7–10].

Correspondence: Jun Lu, M.D., Ph.D., Hepatology and Cancer Biotherapy Ward, Beijing YouAn Hospital, Capital Medical University, No. 8 Xitoutiao, Youanmenwai, Fengtai District, Beijing 100069, People’s Republic of China. Telephone: 86-10-63291028; e-mail: lujun98@ccmu.edu.cn Received December 16, 2020; accepted for publication July 8, 2021; published Online First on July 26, 2021. © AlphaMed Press; the data published online to support this summary are the property of the authors. http://dx.doi.org/10.1002/onc.13899

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The Oncologist 2021;26:e1919–e1930 www.TheOncologist.com

© 2021 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Initial research evaluating the use of α-GalCer, an agonist of CD1d and an NK T-cell stimulator, showed that α-GalCer–loaded dendritic cells (DCs) evoked significant antitumor immune response [11]. Antigen-presenting cells loaded with α-GalCer showed effective immune responses against tumors [7, 12–14]. The adoptive transfer of activated iNKT cells to restore iNKT cell numbers in patients with cancer might be a more promising approach than the intravenous administration of α-GalCer [15]. The safety, feasibility, and clinical effects of adoptive transfer of iNKT cells have been described for patients with melanoma [15], non-small cell lung cancer [16], and head and neck squamous cell carcinoma [17].

The primary goal of this study was to validate the safety and feasibility of using adoptive transfer of in vitro expanded and activated autologous iNKT cells as a potential treatment for patients with HCC. Therefore, we conducted a phase I trial of 10 patients with advanced or recurrent HCC. Three grade 3 adverse events were reported, and most adverse events were grades 1–2, such as transitory fever that might be due to the subcutaneous injection of low-dose interleukin (IL)-2, resolved without treatment within 1 week after iNKT infusion. There were no signs of dose-limiting toxicities (DLTs) and graft-versus-host disease for the doses tested, which ranged from $3 \times 10^7$ cells/m$^2$ given as three infusions to a total of $1.0 \times 10^{10}$ cells administered as a single infusion. Moreover, the cytokine profile of iNKT cells before and after in vitro culture was examined using quantitative reverse-transcription polymerase chain reaction (qRT-PCR). After expansion, the mRNA expression levels increased 4.57–523.77-fold for interferon-gamma (IFN-γ), 3.02–899.48-fold for granzyme B (GzmB), and 5.25–653.51-fold for perforin, but the mRNA expression of IL-4 decreased 2.62–62.85-fold after expansion (Fig. 1). These results indicate that α-GalCer–pulsed in vitro expansion of autologous iNKT cells restores their production of Th1-like cytokines and hence might enhance their antitumor actions.

The median progression-free survival (PFS) was 6.5 (1.5–16) months, whereas the median overall survival (OS) was 13 (1.5–16) months.

Therefore, we consider this therapy to be feasible, safe, and easily combined with other antitumor strategies for patients with advanced HCC, allowing for further clinical studies to refine the technique and evaluate its efficacy.

Figure 1. Expression of cytokines by invariant natural killer T (iNKT) cells before and after in vitro expansion. Quantitative real-time polymerase chain reaction was used to quantify the mRNA expression of T-helper (Th) 1 and Th2 cytokines by iNKT cells before and after cultivation and expansion. (A): The Th1 cytokine, IFN-γ. (B): The Th1 cytokine, perforin. (C): The Th1 cytokine, GzmB. (D): The Th2 cytokine, IL-4. All data were obtained from three independent experiments ($n = 3$). *$p < .001$.

Abbreviations: GzmB, granzyme B; IFN-γ, interferon-gamma; IL-4, interleukin-4; Pt, patient.

© 2021 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Disease: Hepatocellular carcinoma
Stage of Disease/Treatment: Metastatic/advanced
Prior Therapy: No designated number of regimens
Type of Study: Phase I, 3+3
Primary Endpoint: Safety
Secondary Endpoint: Tolerability

Additional Details of Endpoints or Study Design

**Study design and participants:** This prospective clinical trial was a single-center, phase I study (NCT03175679) conducted at Beijing YouAn Hospital, Capital Medical University, Beijing, China, between April 2017 and May 2018. This study was performed in accordance with the Declaration of Helsinki. The protocol and the consent form for the study were approved by the ethics committee of Beijing YouAn Hospital (Jing You Ke Lun [2017] No. 05). All patients provided written informed consent.

The inclusion criteria were as follows: (a) 18–80 years old; (b) HCC of BCLC stage B/C; (c) life expectancy of at least 12 weeks; and (d) adequate hematological and renal function, as indicated by a white blood cell count ≥3 × 10⁹/L, lymphocyte count ≥0.8 × 10⁹/L, platelet count ≥50 × 10⁹/L, hemoglobin concentration ≥85 g/L, serum creatinine concentration ≤1.5 times the upper limit of normal. Patients with tumor recurrence who had received previous chemotherapy or local therapy, such as surgery, radiotherapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous injection, or cryoablation, were eligible for enrolment in the study provided the therapy had been performed at least 4 weeks before study entry. The exclusion criteria were (a) known history of syphilis or infection with human immunodeficiency virus, (b) clinically serious infection, (c) history of stem cell transplantation or organ allotransplantation, (d) history of severe hypertension or cardiac disease, (e) central nervous system tumor, (f) autoimmune disease requiring systemic therapy with immunosuppressive agents, (g) history of allergy to immunotherapy or related drugs, and (h) pregnant or breastfeeding.

**Preparation of iNKT cells:** All procedures were performed according to Good Manufacturing Practice (GMP) standards. Isolation and culture of PBMCs were carried out in a GMP-compliant laboratory (Beijing GeneKey Co. Lab, Beijing, China). Briefly, PBMCs were isolated by leukapheresis using a COM.TEC apheresis system (Fresenius Medical Care, Bad Homburg, Germany) and Lymphoprep density gradient medium (Stemcell Technologies, Cambridge, UK). PBMCs were resuspended in Corning serum-free cell medium KMB581 (Corning Inc., Corning, NY) and stimulated with 100 ng/mL α-GalCer (BioVision, Milpitas, CA) and 100 U/mL animal-free recombinant human interleukin-2 (rhIL-2; Biologend, San Diego, CA) for 48 hours; the rhIL-2 was replenished every other day. Mature, monocyte-derived DCs were obtained from PBMCs stimulated by 1,000 IU/mL granulocyte-macrophage colony-stimulating factor (Biologend) and IL-4 (Biologend) for 1 week. On day 7, iNKT cells were positively sorted using anti-iNKT microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s protocol. The sorted iNKT cells were co-cultured with mature DCs for 14 days, and cells were collected for infusion on day 21. An aliquot of cells was used for immunophenotyping and functional testing. The frequency of iNKT cells was determined using a FACS Canto II cytometer (BD Biosciences, San Jose, CA) and expressed as a percentage of lymphocytes. The criteria for iNKT cell administration included a negative bacterial culture, a negative mycoplasma test result, and an endotoxin level < 0.05 units/mL [22].

**Administration of iNKT cells to patients:** In this phase I dose-escalation study, the patients received different doses of in vitro-expanded autologous iNKT cells through intravenous infusion. The dosage was escalated from 3 × 10⁷ cells/m² to 6 × 10⁷ cells/m² to 9 × 10⁷ cells/m². For each patient, 10%, 30%, and 60% of the total dose of iNKT cells were administered over 3 consecutive days (Table 2). Tegafur (40–60 mg twice a day) was given for 2 weeks before iNKT cell infusion as lymphodepleting chemotherapy. Human IL-2 (25,000 IU/kg per day) was administered for 5 days after iNKT cell infusion to enhance the expansion and persistence of the iNKT cells. Antiviral drugs were administered immediately if a patient tested positive for hepatitis B virus (HBV) DNA or hepatitis C virus (HCV) RNA. DLT was defined as grade ≥3 for any adverse event related to the administration of cultured iNKT cells. If none of the first three patients experienced DLT, another three patients were treated at the next higher dose level. However, if one of the first three patients experienced DLT, three more patients were treated at the same dose level. Dose escalation continued until at least two patients among a cohort of three to six patients experienced DLT. The maximum tolerated dose (MTD) was defined as the last dose level, and the dosage would be up to 1 × 10¹⁰ cells/m² if no MTD was observed after a 3 × 3 design.

**Outcomes and follow-up:** During the first 12 weeks, patients were monitored every 2–4 weeks after infusion to evaluate the safety of the therapy. Laboratory tests and physical examinations were performed at weeks 2, 4, 8, and 12 after iNKT infusion, and the clinical characteristics of the patients were recorded, including HBV infection status (detection of HBV’s antigen), HCV infection status (detection of HCV RNA), serum alpha-fetoprotein (AFP), Child-Pugh score (to assess hepatic function) [23], and Karnofsky performance status score (to evaluate general well-being and activities of daily living) [24]. The patients were then followed up every 3 weeks from 12 weeks after infusion (Fig. 2). All laboratory tests were carried out by the Laboratory Department of Beijing YouAn Hospital. Adverse events and changes in laboratory values were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03. For immuno-monitoring, samples of PBMCs were obtained from patients and frozen in Cellbanker2 (ZENOAQ, Fukushima, Japan) with liquid nitrogen until use.

**Flow cytometric analysis of immune cell subtypes in peripheral blood:** Two samples of peripheral blood (10–15 mL) were collected in two heparin-treated tubes, one of which was used for an automated complete blood count (Sysmex SF–3000 automated hematology analyzer, Toa Medical Electronics, Kobe, Japan) and the other for flow cytometry. PBMCs were
separated using Lymphoprep (Stemcell Technologies). For flow cytometric analysis, PBMCs from all samples were incubated with the following antibodies for 20 minutes at room temperature in the dark: anti-CD3–fluorescein isothiocyanate (FITC), anti–T-cell receptor (TCR) Vα24-Jα18–phycocerythrin (PE), anti-CD8–peridinin chlorophyll protein complex (PerCP)/cytin (Cy) 5.5, anti-CD4/PE/Cy7, anti-CD56–allophycocyanin (APC), anti-CD69–PB, anti-CD279 (programmed death-1 [PD-1])–PE, anti-CD127–APC, anti-CD25–APC/Cy7, anti-CD4–FITC, anti-CD11b–FITC, anti-CD45RA–PE, and anti-C–C chemokine receptor 7 (CCR7)–PerCP/Cy5.5 (BioLegend). Then, the cells were washed once in phosphate-buffered saline and analyzed using a FACSCanto II flow cytometer (BD Biosciences). The frequencies of iNKT cells (CD3+ TCR Vα24/Jα18), NK cells (CD3– CD56+), activated NK cells (CD3+ CD56– CD69+), regulatory T cells (CD4+ CD25+ CD127–), programmed death-1 (CD8– CD8+ PD-1+) T cells, myeloid-derived suppressor cells (CD11b+ CD33+), central memory T cells (CCR7+ CD45RA–), and effecter memory T cells (CCR7– CD45RA–) were measured using FlowJo 7.6.1 software (TreeStar, Ashland, OR). The absolute count of each immune cell type was calculated by multiplying the flow cytometry–derived cell percentage by the absolute lymphocyte count.

Detection of intracellular IFN-γ by immunohistochemistry: PBMCs and cultured iNKT cells were stimulated for 5 hours with phorbol myristic acid (50 ng/mL, Sigma-Aldrich), ionomycin (1 μg/mL, Sigma-Aldrich), and brefeldin A (5 μg/mL, Sigma-Aldrich) at 37°C in 5% CO2. Cells were stained with anti-CD3–APC (BioLegend), anti–TCR Vα24/Jα18–PE (BioLegend), and anti–CD8–PerCP/Cy5.5 (BioLegend) antibodies for 20 minutes at room temperature in the dark. Then, the cells were fixed and permeabilized with fix/perm buffers (BD Biosciences), washed with phosphate-buffered saline, and incubated with anti–IFN-γ–FITC antibody (BioLegend) for 20 minutes. Finally, the cells were washed and analyzed using a FACSCanto II flow cytometer (BD Biosciences). The mean fluorescence intensity (MFI) value for IFN-γ expression by the CD8+ iNKT cell population was obtained using FlowJo 7.6.1 software (TreeStar).

Measurement of the mRNA expressions of IFN-γ, GzmB, IL-4, and perforin by qRT-PCR: iNKT cells were sorted from PBMCs by flow cytometry. Total RNA was isolated from iNKT cells using the Mini BEST Universal RNA Extraction kit (TakaraBio, Shiga, Japan). cDNA was synthesized according to the manufacturer’s protocol. qRT-PCR was performed on a StepOnePlus Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Waltham, MA) using SYBR Premix Ex Taq (Clontech Laboratories, Mountainview, CA). The primers for IFN-γ, GzmB, IL-4, and perforin are shown in Table 3. The polymerase chain reaction conditions were as follows: 95°C for 10 minutes, followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. Data were normalized to the expression of glyceraldehyde 3-phosphate dehydrogenase, which was used as the reference (endogenous control). The 2−ΔΔCT method was used for relative quantification of mRNA level.

Statistical analysis: Data were analyzed using SPSS 17.0 software (SPSS Inc., Chicago, IL) and are presented as means ± SD. Comparisons between two groups were made using two-tailed unpaired Student’s t tests. A value of p < .05 was considered significant.

Investigator’s Analysis

Active and should be pursued further

### Drug Information

| Generic Name          | Autologous iNKT cells |
|-----------------------|-----------------------|
| Company Name          | GeneKey GMP Lab for iNKT Cell Culture |
| Drug Type             | Immune cells |
| Drug Class            | Immune therapy |
| Dose                  | Escalation from 3 × 10⁷ cells/m² to 6 × 10⁷ cells/m² to 9 × 10⁷ cells/m² |
| Route                 | Intravenous infusion |
| Schedule of Administration | 10%, 30%, and 60% of the total dose of iNKT cells were administered over 3 consecutive days for each patient; see Table 2 for details. |

### Dose-Escalation Table

| Dose level | Dose of drug: Autologous iNKT cells | Number enrolled | Number evaluable for toxicity |
|------------|-------------------------------------|-----------------|-------------------------------|
| 1          | 3 × 10⁷ cells/m²                    | 3               | 3                             |
| 2          | 6 × 10⁷ cells/m²                    | 3               | 3                             |
| 3          | 9 × 10⁷ cells/m²                    | 3               | 3                             |
| Exploratory | 1 × 10¹⁰ cells/m²                  | 1               | 1                             |

### Patient Characteristics

| Number of Patients, Male | 9 |
| Number of Patients, Female | 1 |
| Stage | At study entry: BCLC stage B: two patients (20%); stage C: eight patients (80%) |
| Age | Median (range): 51.5 (37–60) years |
| Number of Prior Systemic Therapies | Median (range): 2(0–5) |

© 2021 The Authors.
*The Oncologist* published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Other

Performance status (Child-Pugh): A, seven (70%) patients; B, three (30%) patients
Virus infection:
HBV, eight (80%) patients
HCV: one (10%) patient
None: one (10%) patient
See also Table 1 for detailed patient characteristics.

Cancer Types or Histologic Subtypes
Hepatocellular carcinoma: 10

Primary Assessment Method

| Title | Phase I Clinical Trial of iNKT Cells for HCC |
|-------|---------------------------------------------|
| Number of Patients Screened | 12 |
| Number of Patients Enrolled | 10 |
| Number of Patients Evaluable for Toxicity | 10 |
| Number of Patients Evaluated for Efficacy | 10 |
| Evaluation Method | Survival (PFS and OS); immune Response Evaluation Criteria In Solid Tumors |
| (Median) Duration Assessments PFS | 6.5 months, confidence interval: 1.5 to >16 |
| (Median) Duration Assessments OS | 13 months, confidence interval: 1.5 to >16 |

Outcome Notes

| Evaluation Method | Survival (PFS and OS) |
|-------------------|-----------------------|
| Duration assessments PFS | Median (range): 6.5 (1.5 to >16) months |
| Duration assessments OS | Median (range): 13 (1.5 to >16) months |
| Expression of cytokines after iNKT therapy | IFN-γ in CD8-positive cells (MFI values): increased from 146–231 to 293–458; IFN-γ: increased 4.57–523.77-fold; GzmB: increased 3.02–899.48-fold; Perforin: increased 5.25–653.51-fold; IL-4: decreased 2.62–62.85-fold |
| AFP levels after iNKT therapy | Maintained or decreased |
| Others | For details, see Figs. 2, 3 and supplemental online Figs. 1, 2. |

Adverse Events

| All Dose Levels, All Cycles | NC/NA | 1 | 2 | 3 | 4 | 5 | All Grades |
|-----------------------------|-------|---|---|---|---|---|------------|
| Chill | 80% | 0% | 0% | 0% | 0% | 20% |
| Fever | 70% | 0% | 0% | 0% | 0% | 30% |
| Pain | 90% | 0% | 0% | 0% | 0% | 10% |
| Fatigue (asthenia, lethargy, malaise) | 80% | 0% | 0% | 0% | 20% |
| Anemia | 80% | 0% | 0% | 0% | 0% | 20% |
| Platelet count decreased | 60% | 0% | 0% | 0% | 0% | 40% |
| Neutrophil count decreased | 90% | 0% | 0% | 0% | 0% | 10% |
| White blood cell decreased | 70% | 0% | 0% | 0% | 0% | 30% |
| Blood bilirubin increased | 30% | 0% | 0% | 0% | 0% | 70% |
| Alanine aminotransferase increased | 80% | 0% | 0% | 0% | 0% | 20% |
| Aspartate aminotransferase increased | 60% | 0% | 0% | 0% | 0% | 40% |
| Induration/fibrosis (skin and subcutaneous tissue) | 90% | 0% | 0% | 0% | 0% | 10% |

Adverse Events Legend
Summary of adverse events in all 10 patients for entire time on study (all grades).
Abbreviation: NC/NA, no change from baseline/no adverse event.
Invariant natural killer T (iNKT) cells are a unique lymphocyte subpopulation [25]. iNKT cells are CD1d-restricted, are characterized by an invariant T-cell receptor (TCR) α-chain, and express several receptors in common with natural killer (NK) cells [25, 26]. These lymphocytes share distinct recognition systems with T cells or NK cells [27]. iNKT cells recognize glycolipid ligands presented by CD1d [28–30], which is a monomeric major histocompatibility complex class-I-like glycoprotein that binds distinct lipid-based antigens [28].

After activation, iNKT cells respond very rapidly to TCR and/or cytokine signals with immediate and copious production of cytokines such as interferon-gamma (IFN-γ) and interleukin-4 (IL-4), which transactivate other receptors in common with NK cells, T cells, B cells, and dendritic cells (DCs) [25, 31]. Beside the production of cytokines, iNKT cells also have potent antitumor activity mediated through Fas ligand and perforin-dependent mechanisms [11, 32]. Therefore, iNKT cells exert potent antitumor and immunoregulatory effects by bridging the innate and adaptive immune responses.

Early systemic administration of alpha-galactosylceramide (α-GalCer) or α-GalCer–loaded DCs generated in vitro can generate immunological responses against various solid tumors, and therapeutic effects have been observed in patients with cancer through a reversal of NK T-cell deficiency [7, 12, 33, 34]. Recent clinical studies of α-GalCer–loaded monocyte-derived antigen-presenting cells, peripheral blood mononuclear cells (PBMCs) cultured with α-GalCer, and iNKT cells isolated with a monoclonal antibody (6B11) have described objective immune responses against solid tumors [7, 12, 15]. In this study, patients underwent leukapheresis to isolate PBMCs, which were first pulsed with α-GalCer and then subjected to positive selection using anti-iNKT microbeads to increase the purity of Vα24 NK T cells (up to 90%). The purified cells were then co-cultured with α-GalCer–loaded mature antigen-presenting cells, which present glycolipid antigen to the iNKT cells and thereby activate them.

The frequency of iNKT cells among freshly isolated PBMCs was analyzed by flow cytometry. Representative data for one patient are shown in Figure 3A and B: iNKT cell purity was increased from 0.16% to 90.24% after in vitro expansion. The median iNKT cell expansion rate for the 10 patients was 63,500-fold (range, 13,500-fold to 135,300-fold) after 21 days of cultivation, and the purity of the iNKT cells increased from 0.05%–1.48% to 85.66%–94.55% (Table 2). The expression of IFN-γ in CD8+ iNKT cells was upregulated after expansion in all 10 patients, with mean fluorescence intensity values increasing from 146–231 (range among the 10 patients) to 293–458 (Fig. 3C).

After expansion, the mRNA expression levels increased 4.57–523.77-fold for IFN-γ, 3.02–899.48-fold for granzyme B (GzmB), and 5.25–653.51-fold for perforin, but the mRNA expression of IL-4 decreased 2.62–62.85-fold after expansion (Fig. 1).

Hence, successful activation of iNKT cells was demonstrated by significant increases in the mRNA levels of Thelper 1 (Th1) cytokines (IFN-γ, perforin, and GzmB; Fig. 1A–C). The human CD8+ iNKT subset is similar to NKT1 cells in mice, showing increased IFN-γ secretion and cytotoxic function when activated [33, 35]. We also detected an increase in the expression of IFN-γ protein in CD8+ iNKT cells after in vitro expansion (Fig. 3C). A restoration of iNKT cell immune function after in vitro expansion has also been reported in the setting of non-small cell lung cancer [16]. iNKT cells are noncirculating, tissue-resident lymphocytes. Previous studies have reported that the frequency of circulating Vα24 NK T

| Name                                      | Grade | Attribution |
|-------------------------------------------|-------|-------------|
| Cirrhosis and upper gastrointestinal bleeding | 5     | Unrelated   |
| Refractory cholangitis/toxic megacolon    | 5     | Unrelated   |
| Rupture of the tumor                      | 5     | Unrelated   |

**Dose-Limiting Toxicities Table**

| Dose level | Dose of Drug: Autologous iNKT cells | Number enrolled | Number evaluable for toxicity | Number with a DLT |
|------------|--------------------------------------|-----------------|------------------------------|-------------------|
| 1          | 3 × 10^7 cells/m²                    | 3               | 3                            | 0                 |
| 2          | 6 × 10^7 cells/m²                    | 3               | 3                            | 0                 |
| 3          | 9 × 10^7 cells/m²                    | 3               | 3                            | 0                 |
| Exploratory| 1 × 10^10 cells/m²                   | 1               | 1                            | 0                 |

**Assessment, Analysis, and Discussion**

**Completion**

**Investigator’s Assessment**

Study completed

Active and should be pursued further
cells before the expansion is low and shows a substantial variation (0.01%–2%) [36, 37], and the fold-increase in Vα24 NK T cell number after in vitro expansion varies among patients [33]. The protocol described in this study (which involves microbead-based isolation) provides a reproducibly high number of iNKT cells for adoptive infusion and thus will greatly facilitate the future assessment of the efficacy of this therapeutic approach in patients.

In this study, the number of iNKT cells (baseline, 4.15–30.80 × 10^3/L) rapidly increased 1.5–13.0-fold (to 13.13–60.81 × 10^3/L) at week 2 and then decreased to 7.60–37.8 × 10^3/L at week 4 and to baseline levels from week 8 onward (Fig. 4). A previous study of patients with melanoma found that circulating levels of NK cells and CD69^+ NK cells increased after iNKT cell infusion [15]. Since central memory T cells have potent antitumor activity characterized by memory and persistence [38, 39], this raises the possibility that antigens specific to hepatocellular cancer (HCC) may have activated an antitumor response.

Survival is typically short (<6 months) in patients with advanced HCC. Although none of the patients in this study exhibited a complete response or partial response to iNKT cell infusion, five patients were still alive at the end of follow-up, one of whom had no tumor recurrence and good quality of life. In addition, serum alpha-fetoprotein (AFP) value decreased in three patients within 2 weeks of iNKT cell administration (Fig. 4), directly suggesting an antitumor effect. Therefore, the adoptive transfer of in vivo–expanded iNKT cells to patients with HCC is well tolerated and associated with only minor adverse events.

Data for overall survival and progression-free survival are presented in Table 4. Patient 3 was still alive without tumor recurrence. Patients 1, 5, 6, and 7 exhibited tumor progression at 11, 6, 5.5, and 7 months after iNKT infusion, respectively, and were alive without extrahepatic metastasis. Tumor progression was treated by transcatheter arterial chemoembolization and radiofrequency ablation in patients 5 and 6 and by surgical resection in patients 1 and 7.

AFP is a frequently used marker for the diagnosis of HCC and monitoring of therapeutic effect, and its level is elevated in around 50% of patients with HCC. Four patients (1, 3, 5, and 7) had AFP levels within the normal range (<7 ng/mL) before treatment, and serum AFP levels in these patients were maintained within the normal range following iNKT cell therapy (Fig. 5). Six patients (2, 4, 6, 8, 9, and 10) had abnormal levels of AFP (Fig. 5).

Patients 2, 4, 8, and 9 died without the occurrence of tumor progression. Patients 4, 8, and 9 were confirmed to have severe cirrhosis, multiple diffuse tumors, portal vein tumor thrombosis, and high-risk esophageal varices (grade 3 on gastroscopic examination) and gastric varices before iNKT cell therapy. These three patients died of upper gastrointestinal bleeding at 11, 1.5, and 1.5 months, respectively, after treatment. Patient 2 was initially diagnosed with cholecystitis and cholestasis caused by biliary bacterial infection before iNKT therapy. Patient 2 died due to refractory bile duct infection and toxic megacolon at 1.5 months. Patient 10 died of spontaneous rupture of the tumor at 7 months after iNKT cell therapy (Table 4). Although these were serious adverse events, they were considered unrelated to treatment and instead related to underlying disease.

All adverse events occurring within 4 weeks of therapy are documented in Table 5. Most adverse events were of grade 1 to 3, grade 4 and 5 were not observed. ALL adverse events resolved without treatment within several days. The common adverse events were fever, elevated TBIL, elevated AST and decreased platelet count. Although the increases in serum AST and/or TBIL in patients 2 and 9 were of grade 3, the levels in both patients recovered within one week without treatment.

This study has some limitations. First, this was a single-center study, so the generalizability of the findings is not known. Second, the sample size was small, limiting the strength of the conclusions that may be drawn. Third, the cohort of 10 patients included only one woman, so possible gender-related differences could not be evaluated. Fourth, as this was a phase I trial focusing on dosage and safety, comparator groups (such as a control group) were not included. Finally, the final dose was only tried exploratively in the 10th patient. No maximum tolerated dose was found, and the safety was very good. Considering that the first three dosages are commonly used, the study was stopped.

In conclusion, the administration of in vitro–expanded autologous iNKT cells to patients with HCC is safe and well tolerated. There were no severe adverse events related to the infusion of iNKT cells, and most of the adverse events that occurred were of grades 1–2 and resolved within a week without treatment. Notably, the expanded iNKT cells produced Th1 cytokines that might enhance their anti-tumor activity. Further studies are merited to investigate the antitumor effects of iNKT cell therapy in patients with HCC.

Acknowledgments
We appreciate the help from the GeneKey GMP Lab for iNKT cell culture. This study was supported by grants from the Capital Health Research and Development Projects (grant number: 2018-1-2181), Capital Characteristic Clinical Application Research (grant number: Z181100001718191), and Beijing Municipal Administration of Hospitals Incubating Program (grant number: PX2019063).

Disclosures
The authors indicated no financial relationships.
REFERENCES

1. Molling JW, Moreno M, de Groot J et al. Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases. Immunol Lett 2008;118:36–43.

2. Wen X, Kim S, Xiong R et al. A subset of CD8α− invariant NKT cells in a humanized mouse model. J Immunol 2015;195:1459–1469.

3. Nakui M, Ohta A, Sekimoto M et al. Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells. Clin Exp Metastasis 2000;18:147–153.

4. Kawano T, Cui J, Koezuka Y et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 1998;95:5690–5693.

5. Cariani E, Pilli M, Zerbini A et al. Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS One 2012;7:e32493.

6. Hishiki T, Mise N, Harada K et al. Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with malignant solid tumors. Pediatr Surg Int 2018;34:169–176.

7. Schneider FS, Scheper RJ, von Blomberg BM et al. Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol 2011;140:130–141.

8. Wu TN, Lin KH, Chang YJ et al. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy. Proc Natl Acad Sci USA 2011;108:17275–17280.

9. Nagato K, Motohashi S, Ishibashi F et al. Accumulation of activated invariant natural killer T cells in the tumor microenvironment after alpha-galactosylceramide-pulsed antigen presenting cells. J Clin Immunol 2012;32:1071–1081.

10. Exley MA, Lynch L, Varghese B et al. Developing an understanding of the roles of CD1d-restricted T cell subsets in cancer: Reversing the current split in immune system: NKT cells rapidly activate NK cells. J Immunol 1999;163:4647–4650.

11. Carnaud C, Lee D, Donnars O et al. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999;163:4647–4650.

12. Smyth MJ, Thia KY, Street SE et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661–668.

13. Heng F, Nakajima N, Wu L et al. A glycolipid adjuvant, 7DW8-5, enhances the protective immune response to the current split influenza vaccine in mice. Front Microbiol 2019;10:2157.

14. Ishikawa A, Motohashi S Ishikawa E, et al. A phase I study of alpha-galactosylceramide-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2006;12:6079–6086.

15. Kuni N, Horiguchi S, Motohashi S et al. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck cancer. Cancer Sci 2009;100:1092–1098.

16. Crosby CM, Kronenberg M. Tissue-specific functions of invariant natural killer T cells. Nat Rev Immunol 2015;18:559–574.

17. Nakagawa R, Motoki K, Ueno H et al. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res 1998;58:1202–1207.

18. Fuji N, Ueda Y, Fujwara H et al. Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver. Clin Cancer Res 2000;6:3380–3387.

19. Bracard G, Cesson V, Devevre E et al. Enrichment of human CD4+ V(α)24/Vβ eta1 invariant NKT cells in intrahepatic malignant tumors. J Immunol 2009;182:5140–5151.

20. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China 2015. Beijing: China Medical Science Press, 2015.

21. Pugh RN, Murray-Lyon IM, Dawson JL et al. Transaction of the osseous organ for bleeding osseous varices. Br J Surg 1973;60:646–649.

22. Peus D, Newcomb N, Hofer S. Appraisal of the Karnofsky performance status and proposal of a simple algorithmic system for its evaluation. BMC Med Inform Decis Mak 2013;13:72.

23. Godfrey DI, Hammond KJ, Poulton LD et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005;102:9571–9576.

24. Zhou J, Dudley ME, Rosenberg SA et al. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 2005;28:53–62.
**Figure 2.** Clinical trial protocol.
Abbreviations: IL-2, interleukin-2; iNKT, invariant natural killer T cells.

---

**Table 1.** Clinical characteristics of the 10 patients with hepatocellular carcinoma

| Patient no. | Age, yr | Sex | KPS | Viral infection | Child-Pugh | Prior treatment (times) | Vascular invasion | Metastasis | BCLC stage |
|-------------|---------|-----|-----|----------------|------------|-------------------------|------------------|------------|------------|
| 1           | 60      | M   | 1   | HCV           | A          | TACE (2)/RFA (1)        | N                | N          | C          |
| 2           | 50      | M   | 2   | HBV           | B          | non treatment           | Y (PVTT)         | N          | C          |
| 3           | 50      | M   | 1   | HBV           | A          | TACE (3)/RFA (2)        | Y                | N          | C          |
| 4           | 51      | M   | 1   | HBV           | A          | Surgery (1)             | N                | Y          | C          |
| 5           | 59      | M   | 1   | HCV           | A          | TACE (1)                | N                | Y          | C          |
| 6           | 44      | M   | 1   | HBV           | A          | TACE (2)/RFA (1)        | N                | Y          | C          |
| 7           | 52      | M   | 1   | HBV           | A          | TACE (2)/RFA (1)        | N                | N          | B          |
| 8           | 37      | M   | 2   | HBV           | A          | non treatment           | Y (PVTT)         | N          | C          |
| 9           | 59      | F   | 2   | HBV           | B          | TACE (1)/RFA (1)        | Y                | N          | C          |
| 10          | 53      | M   | 1   | non HBV/   | A          | TACE (1)/RFA (1)        | N                | N          | B          |

Abbreviations: BCLC, Barcelona Clinic Liver Cancer; F, female; HBV, hepatitis B virus; HCV, hepatitis C virus; KPS, Karnofsky performance status score; M, male; N, no; PVTT, portal vein tumor thrombosis; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization; Y, yes.

---

**Table 2.** Summary of invariant natural killer T-cell purity before and after expansion and the infusion dosages used

| Patient no. | Pre-expansion iNKT cell purity, % | Post-expansion iNKT cell purity, % | iNKT cell dosage, cells/m² | Total iNKT cell dose | iNKT cell dose, infusion 1 | iNKT cell dose, infusion 2 | iNKT cell dose, infusion 3 |
|-------------|-----------------------------------|-----------------------------------|---------------------------|----------------------|-----------------------------|-----------------------------|-----------------------------|
| 1           | 0.16                              | 90.24                             | 3 × 10⁷                   | 5.88 × 10⁷           | 5.88 × 10⁶                   | 1.76 × 10⁶                   | 3.50 × 10⁷                   |
| 2           | 1.48                              | 88.91                             | 3 × 10⁷                   | 5.04 × 10⁷           | 5.04 × 10⁶                   | 1.51 × 10⁶                   | 3.02 × 10⁷                   |
| 3           | 0.15                              | 85.66                             | 3 × 10⁷                   | 5.58 × 10⁷           | 5.58 × 10⁶                   | 1.67 × 10⁷                   | 3.35 × 10⁷                   |
| 4           | 0.31                              | 94.55                             | 6 × 10⁷                   | 1.06 × 10⁸           | 1.06 × 10⁷                   | 3.18 × 10⁷                   | 6.36 × 10⁸                   |
| 5           | 0.65                              | 90.01                             | 6 × 10⁷                   | 1.02 × 10⁸           | 1.02 × 10⁷                   | 3.06 × 10⁷                   | 6.12 × 10⁸                   |
| 6           | 0.22                              | 86.94                             | 6 × 10⁷                   | 1.13 × 10⁸           | 1.13 × 10⁷                   | 3.39 × 10⁷                   | 6.78 × 10⁸                   |
| 7           | 0.06                              | 86.63                             | 9 × 10⁷                   | 1.75 × 10⁸           | 1.75 × 10⁷                   | 5.25 × 10⁷                   | 1.05 × 10⁸                   |
| 8           | 0.16                              | 89.72                             | 9 × 10⁷                   | 1.62 × 10⁸           | 1.62 × 10⁷                   | 4.86 × 10⁷                   | 9.72 × 10⁷                   |
| 9           | 0.05                              | 89.12                             | 9 × 10⁷                   | 1.67 × 10⁸           | 1.67 × 10⁷                   | 5.01 × 10⁷                   | 1.00 × 10⁸                   |
| 10          | 0.12                              | 88.3                              | 1.0 × 10¹⁰                | 1.0 × 10¹⁰           | 1.0 × 10¹⁰                   | 0                           | 0                           |

Abbreviation: iNKT, invariant natural killer T.
Table 3. Primers used for the quantitative real-time polymerase chain reaction

| Gene product                        | Sequence (5′ → 3′)                  |
|-------------------------------------|-------------------------------------|
| Interleukin-4                       | Forward: CCGTAACAGACATCTTTGCTGCC    |
|                                     | Reverse: GAGTGTCCTTCTCATGTGGGCT     |
| Interferon-gamma                    | Forward: TGATGTCCACCGCAAAGC         |
|                                     | Reverse: CGACCTGGAACACCATCTGA       |
| Granzyme B                          | Forward: CCCTGGAAAAACACTCAACA       |
|                                     | Reverse: GCAACACTCAATGGTACTGTGA     |
| Glyceraldehyde 3-phosphate dehydrogenase | Forward: TGGGGCATCAATGGATTTGG     |
|                                     | Reverse: ACACCATGTATTCCGGGTCAAT     |

Figure 3. Characteristics of the invariant natural killer T (iNKT) cells. Cells were stained with monoclonal antibodies specific for CD3 and Vα24Jα18 and analyzed by flow cytometry. (A): Flow cytometric dot plot showing CD3 and Vα24Jα18 expression in peripheral blood mononuclear cells isolated from one patient. iNKT cell purity was 0.16%. (B): Flow cytometric dot plot showing the purity of the expanded iNKT cells (90.24%) in the same patient as above. (C): Comparison of IFN-γ expression levels in CD8-positive iNKT cells before and after expansion. IFN-γ expression was evaluated using immunohistochemistry with a calculation of the mean fluorescence intensity. All data were obtained from three independent experiments (n = 3). *p < .001.

Abbreviations: IFN-γ, interferon-gamma; MFI, mean fluorescence intensity; Pt, patient; TCR Va 24, T-cell receptor Vα24.
Figure 4. Changes in the numbers of immune cells after the infusion of iNKT cells. The absolute cell count ($\times 10^3/L$) for each type of immune cell was obtained by multiplying the immune cell percentage (measured by flow cytometry) by the absolute lymphocyte count (measured with a hematology analyzer). (A): iNKT cells. (B): NK cells. (C): Activated NK cells. (D): CD8-positive PD-1–positive cells. (E): Regulatory T cells. (F): Myeloid-derived suppressor cells. (G): Central memory T cells. (H): Effector memory T cells. All data were obtained from three independent experiments ($n = 3$).

Abbreviations: iNKT, invariant natural killer T cells; MDSC, myeloid-derived suppressor cells; NK, natural killer cells; PD-1, programmed death-1; Pt, patient; TCM, central memory T cells; TEM, effector memory T cells; Treg, regulatory T cells; WK, week.

| Patient | PFS, months | OS, months | Cause of death                          |
|---------|-------------|------------|-----------------------------------------|
| 1       | 11          | >16        |                                         |
| 2       | 1.5         | 1.5        | Intra-abdominal bacterial infection      |
| 3       | >16         | >16        |                                         |
| 4       | 11          | 11         | Gastric variceal bleeding               |
| 5       | 6           | >16        |                                         |
| 6       | 5.5         | >15        |                                         |
| 7       | 7           | >15        |                                         |
| 8       | 1.5         | 1.5        | Gastric variceal bleeding               |
| 9       | 1.5         | 1.5        | Gastric variceal bleeding               |
| 10      | 7           | 7          | Spontaneous rupture of hepatocellular carcinoma |

Abbreviations: OS, overall survival; PFS, progression-free survival.
Table 5. Adverse events

| Adverse event                        | Grade 1, n | Grade 2, n | Grade 3, n | Total, n |
|--------------------------------------|------------|------------|------------|----------|
| Chills                               | 2          | 0          | 0          | 2        |
| Fever                                | 3          | 0          | 0          | 3        |
| Pain                                 | 1          | 0          | 0          | 1        |
| Fatigue                              | 2          | 0          | 0          | 2        |
| Anemia                               | 2          | 0          | 0          | 2        |
| Decreased platelet count             | 1          | 3          | 0          | 4        |
| Decreased neutrophil count           | 1          | 0          | 0          | 1        |
| Decreased white blood cell count     | 3          | 0          | 0          | 3        |
| Increased blood bilirubin level      | 5          | 0          | 2          | 7        |
| Increased alanine transaminase level | 2          | 0          | 0          | 2        |
| Increased aspartate transaminase level | 3        | 0          | 1          | 4        |
| Subcutaneous induration              | 1          | 0          | 0          | 1        |
| Total                                | 26         | 3          | 3          | 32       |

Figure 5. Alpha-fetoprotein levels before and after the infusion of invariant natural killer T cells. Abbreviations: AFP, alpha-fetoprotein; Pt, patient; WK, week.